2023
Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma
Lu L, Risch E, Halaban R, Zhen P, Bacchiocchi A, Risch H. Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. International Immunopharmacology 2023, 118: 110092. PMID: 37004344, DOI: 10.1016/j.intimp.2023.110092.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeSoluble PD-L1 (sPD-L1) levelsPD-L1 ratioPD-L1 levelsSoluble PD-1Soluble PD-L1PD-L1PD-1Patient survivalSurvival statusPD-1/PD-L1Immune checkpoints PD-1T cell exhaustionPatients' survival statusSolid tumor typesInitial immunotherapyCheckpoint blockadeMelanoma patientsPoor prognosisRetrospective studyPatient responseCell exhaustionTumor typesMelanomaSurvival
2021
“Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”
Bade BC, Gan G, Li F, Lu L, Tanoue L, Silvestri GA, Irwin ML. “Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”. BMC Cancer 2021, 21: 352. PMID: 33794808, PMCID: PMC8015735, DOI: 10.1186/s12885-021-08084-0.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced-stage lung cancerStage lung cancerUsual carePhysical activityIntervention groupQuality of lifeLung cancerEligible patientsStage III/IV non-small cell lung cancerLow baseline physical activityHome-based physical activityAdvanced stage diseaseSoluble PD-1Stage IV adenocarcinomaBaseline physical activityMinority of patientsCell lung cancerPatient-reported outcomesEffects of exerciseRole functioning domainsLung cancer biologyAspects of QoL.Mobile health interventionsCancer biomarkers